Skip to main content
SpringerLink
Log in

Dyslipidemia in Women: Etiology and Management

  • Chapter
  • First Online:
Stroke Revisited: Dyslipidemia in Stroke

Part of the book series: Stroke Revisited ((STROREV))

Abstract

This chapter summarizes the current knowledge regarding the prevalence of dyslipidemia in women, different response to therapy, and strategies to prevent and treat dyslipidemia during pregnancy and in postmenopausal women. Cardiovascular disease (CVD), particularly coronary heart disease (CHD), is the leading cause of death among women aged 60 and older. Appreciation of the differences between men and women in CHD risk factors and presentations can assist in treatment decisions. Some factors are unique to women, including reproductive status and menopause that increase the risk of dyslipidemia and consequently CVD in women. Menopause is associated with an elevation in LDL-cholesterol level in addition to threefold increase in the risk of CVD. Total cholesterol, very-low-density lipoprotein (VLDL) cholesterol, and triglyceride increase markedly after menopause. Dyslipidemias in post-menopausal women are particularly atherogenic and tend to cluster with other metabolic and non-metabolic risk factors. Randomized trials of statins for primary and secondary prevention of coronary heart disease suggest that statins have been effective in reducing the morbidity and mortality of CHD and should be considered as a first-line therapy for lipid lowering. In addition, pregnancy, known as an insulin resistance state, is associated with elevation of both cholesterol and triglyceride. Statins are contraindicated during pregnancy but omega-3 fatty acids may be used for hypertriglyceridemia. Those with genetic lipid disorders should consider consulting a clinician with lipid expertise before starting the pregnancy. This is particularly important due to the narrowed therapeutic options of lipid management which are available for pregnant women.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 79.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, et al. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation. 2018;137(12):e67–e492. https://doi.org/10.1161/cir.0000000000000558.

    Article  PubMed  Google Scholar 

  2. Eaker ED, Chesebro JH, Sacks FM, Wenger NK, Whisnant JP, Winston M. Cardiovascular disease in women. Circulation. 1993;88(4 Pt 1):1999–2009. https://doi.org/10.1161/01.cir.88.4.1999.

    Article  CAS  PubMed  Google Scholar 

  3. Harikrishnan S, Jeemon P, Mini G, Thankappan K, Sylaja P. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. 2018.

    Google Scholar 

  4. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP et al. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139–e596. https://doi.org/10.1161/CIR.0000000000000757

  5. Kannel WB, Wilson PW. Risk factors that attenuate the female coronary disease advantage. Arch Intern Med. 1995;155(1):57–61.

    Article  CAS  PubMed  Google Scholar 

  6. Mehta LS, Beckie TM, DeVon HA, Grines CL, Krumholz HM, Johnson MN, et al. Acute myocardial infarction in women: a scientific statement from the American Heart Association. Circulation. 2016;133(9):916–47. https://doi.org/10.1161/cir.0000000000000351.

    Article  CAS  PubMed  Google Scholar 

  7. Williams RA. Cardiovascular disease in African American women: a health care disparities issue. J Natl Med Assoc. 2009;101(6):536–40. https://doi.org/10.1016/s0027-9684(15)30938-x.

    Article  PubMed  Google Scholar 

  8. Welty FK. Cardiovascular disease and dyslipidemia in women. Arch Intern Med. 2001;161(4):514–22.

    Article  CAS  PubMed  Google Scholar 

  9. Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women—2011 update: a guideline from the American Heart Association. J Am Coll Cardiol. 2011;57(12):1404–23.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Kannel WB, Wilson PW. Efficacy of lipid profiles in prediction of coronary disease. Am Heart J. 1992;124(3):768–74.

    Article  CAS  PubMed  Google Scholar 

  11. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke Statistics-2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139–596. https://doi.org/10.1161/cir.0000000000000757.

    Article  PubMed  Google Scholar 

  12. Stevenson JC, Crook D, Godsland IF. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis. 1993;98(1):83–90. https://doi.org/10.1016/0021-9150(93)90225-j.

    Article  CAS  PubMed  Google Scholar 

  13. Cagnacci A, Venier M. The controversial history of hormone replacement therapy. Medicina (Kaunas, Lithuania). 2019;55(9). https://doi.org/10.3390/medicina55090602

  14. Manolio TA, Pearson TA, Wenger NK, Barrett-Connor E, Payne GH, Harlan WR. Cholesterol and heart disease in older persons and women. Review of an NHLBI workshop. Ann Epidemiol. 1992;2(1–2):161–76. https://doi.org/10.1016/1047-2797(92)90051-q.

    Article  CAS  PubMed  Google Scholar 

  15. Campos H, McNamara JR, Wilson PW, Ordovas JM, Schaefer EJ. Differences in low density lipoprotein subfractions and apolipoproteins in premenopausal and postmenopausal women. J Clin Endocrinol Metab. 1988;67(1):30–5. https://doi.org/10.1210/jcem-67-1-30.

    Article  CAS  PubMed  Google Scholar 

  16. Fonseca MIH, da Silva IT, Ferreira SRG. Impact of menopause and diabetes on atherogenic lipid profile: is it worth to analyse lipoprotein subfractions to assess cardiovascular risk in women? Diabetol Metab Syndr. 2017;9:22. https://doi.org/10.1186/s13098-017-0221-5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Johnson CL, Rifkind BM, Sempos CT, Carroll MD, Bachorik PS, Briefel RR, et al. Declining serum total cholesterol levels among US adults. The National Health and nutrition examination surveys. JAMA. 1993;269(23):3002–8.

    Article  CAS  PubMed  Google Scholar 

  18. Wilson PW, Kannel WB, Silbershatz H, D’Agostino RB. Clustering of metabolic factors and coronary heart disease. Arch Intern Med. 1999;159(10):1104–9. https://doi.org/10.1001/archinte.159.10.1104.

    Article  CAS  PubMed  Google Scholar 

  19. Duncan MS, Vasan RS, Xanthakis V. Trajectories of blood lipid concentrations over the adult life course and risk of cardiovascular disease and all-cause mortality: observations from the Framingham study over 35 years. J Am Heart Assoc. 2019;8(11):e011433. https://doi.org/10.1161/jaha.118.011433.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Abbott RD, Wilson PW, Kannel WB, Castelli WP. High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction. The Framingham Study. Arteriosclerosis (Dallas, Tex). 1988;8(3):207–11. https://doi.org/10.1161/01.atv.8.3.207

  21. Sultan N, Nawaz M, Sultan A, Fayaz M, Baseer A. Effect of menopause on serum HDL-cholesterol level. J Ayub Med College, Abbottabad. 2003;15(3):24–6.

    Google Scholar 

  22. Chemnitius JM, Winkel H, Meyer I, Schirrmacher K, Armstrong VW, Kreuzer H, et al. Age related decrease of high density lipoproteins (HDL) in women after menopause. Quantification of HDL with genetically determined HDL arylesterase in women with healthy coronary vessels and in women with angiographically verified coronary heart disease. Medizinische Klinik (Munich, Germany: 1983). 1998;93(3):137–45. https://doi.org/10.1007/bf03044831

  23. Garber AJ. Vascular disease and lipids in diabetes. Med Clin. 1998;82(4):931–48.

    CAS  Google Scholar 

  24. Association AD. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2000;23:S32.

    Google Scholar 

  25. Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham study. JAMA. 1986;256(20):2835–8. https://doi.org/10.1001/jama.1986.03380200073024.

    Article  CAS  PubMed  Google Scholar 

  26. McBride P. Triglycerides and risk for coronary artery disease. Curr Atheroscler Rep. 2008;10(5):386–90. https://doi.org/10.1007/s11883-008-0060-9.

    Article  CAS  PubMed  Google Scholar 

  27. Harchaoui K, Visser M, Kastelein J, Stroes E, Dallinga-Thie G. Triglycerides and cardiovascular risk. Curr Cardiol Rev. 2009;5(3):216–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Lindquist P, Bengtsson C, Lissner L, Björkelund C. Cholesterol and triglyceride concentration as risk factors for myocardial infarction and death in women, with special reference to influence of age. J Intern Med. 2002;251(6):484–9.

    Article  CAS  PubMed  Google Scholar 

  29. Campos H, Mcnamara JR, Wilson PW, ORDOVAS JM, SCHAEFER EJ. Differences in low density lipoprotein subfractions and apolipoproteins in premenopausal and postmenopausal women. J Clin Endocrinol Metabol. 1988;67(1):30–5.

    Article  CAS  Google Scholar 

  30. de Aloysio D, Gambacciani M, Meschia M, Pansini F, Modena AB, Bolis PF, et al. The effect of menopause on blood lipid and lipoprotein levels. Atherosclerosis. 1999;147(1):147–53. https://doi.org/10.1016/S0021-9150(99)00315-9.

    Article  PubMed  Google Scholar 

  31. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a metaanalysis of population-based prospective studies. J Cardiovasc Risk. 1996;3(2):213–9.

    Article  CAS  PubMed  Google Scholar 

  32. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003;52(5):1210–4. https://doi.org/10.2337/diabetes.52.5.1210.

    Article  CAS  PubMed  Google Scholar 

  33. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the third National Health and nutrition examination survey, 1988-1994. Arch Intern Med. 2003;163(4):427–36. https://doi.org/10.1001/archinte.163.4.427.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C. Definition of metabolic syndrome. Circulation. 2004;109(3):433–8. https://doi.org/10.1161/01.CIR.0000111245.75752.C6

  35. Knopp RH. Risk factors for coronary artery disease in women. Am J Cardiol. 2002;89(12 Suppl 1):28–34. https://doi.org/10.1016/S0002-9149(02)02409-8

  36. Goldschmid MG, Barrett-Connor E, Edelstein SL, Wingard DL, Cohn BA, Herman WH. Dyslipidemia and ischemic heart disease mortality among men and women with diabetes. Circulation. 1994;89(3):991–7. https://doi.org/10.1161/01.cir.89.3.991.

    Article  CAS  PubMed  Google Scholar 

  37. Garber AJ. Vascular disease and lipids in diabetes. Med Clin North Am. 1998;82(4):931–48. https://doi.org/10.1016/s0025-7125(05)70030-4.

    Article  CAS  PubMed  Google Scholar 

  38. Rich-Edwards JW, Manson JE, Hennekens CH, Buring JE. The primary prevention of coronary heart disease in women. N Engl J Med. 1995;332(26):1758–66. https://doi.org/10.1056/nejm199506293322607.

    Article  CAS  PubMed  Google Scholar 

  39. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2003;26(Suppl 1):S33–50. https://doi.org/10.2337/diacare.26.2007.s33

  40. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999;282(24):2340–6. https://doi.org/10.1001/jama.282.24.2340.

    Article  CAS  PubMed  Google Scholar 

  41. Collins R, Peto R, Armitage J. The MRC/BHF Heart protection study: preliminary results. Int J Clin Pract. 2002;56(1):53–6.

    PubMed  Google Scholar 

  42. Hodis HN, Mack WJ, Lobo R. Antiatherosclerosis interventions in women. Am J Cardiol. 2002;90(1a):17f–21f. https://doi.org/10.1016/s0002-9149(02)02420-7

  43. LaRosa JC. Prevention and treatment of coronary heart disease: who benefits? Circulation. 2001;104(14):1688–92.

    Article  CAS  PubMed  Google Scholar 

  44. Clearfield M, Downs JR, Weis S, Whitney EJ, Kruyer W, Shapiro DR, et al. Air force/Texas coronary atherosclerosis prevention study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women. J Womens Health Gend Based Med. 2001;10(10):971–81.

    Article  CAS  PubMed  Google Scholar 

  45. Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA study): a prospective randomised controlled trial. Lancet. 2006;368(9542):1155–63.

    Article  CAS  PubMed  Google Scholar 

  46. Joseph P, Lonn E, Bosch J, Lopez P, Zhu J, Keltai M, et al. Long-term effects of statins, blood pressure-lowering, and both on erectile function in persons at intermediate risk for cardiovascular disease: a substudy of the Heart outcomes prevention Evaluation-3 (HOPE-3) randomized controlled trial. Can J Cardiol. 2018;34(1):38–44.

    Article  PubMed  Google Scholar 

  47. Mora S, Glynn RJ, Hsia J, MacFadyen JG, Genest J, Ridker PM. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the justification for the use of statins in prevention: an intervention trial evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation. 2010;121(9):1069–77. https://doi.org/10.1161/circulationaha.109.906479.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397–405. https://doi.org/10.1016/s0140-6736(14)61368-4.

    Article  PubMed  Google Scholar 

  49. Kostis WJ, Cheng JQ, Dobrzynski JM, Cabrera J, Kostis JB. Meta-analysis of statin effects in women versus men. J Am Coll Cardiol. 2012;59(6):572–82. https://doi.org/10.1016/j.jacc.2011.09.067.

    Article  CAS  PubMed  Google Scholar 

  50. Group SSSS. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet. 1994;344(8934):1383–9.

    Google Scholar 

  51. Lewis SJ, Sacks FM, Mitchell JS, East C, Glasser S, Kell S, et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. J Am Coll Cardiol. 1998;32(1):140–6.

    Article  CAS  PubMed  Google Scholar 

  52. Group L-TIwPiIDS. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339(19):1349–57.

    Article  Google Scholar 

  53. Waters D, Higginson L, Gladstone P. Canadian coronary atherosclerosis intervention trial. Circulation. 1994;89:959–68.

    Article  CAS  PubMed  Google Scholar 

  54. Heart CR, Protection Study Collaborative Group. MRC/BHF Heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005–16.

    Article  CAS  Google Scholar 

  55. Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus ‘usualcare’ in secondary coronary heart disease prevention. Curr Med Res Opin. 2002;18(4):220–8.

    Article  PubMed  Google Scholar 

  56. Gutierrez J, Ramirez G, Rundek T, Sacco RL. Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis. Arch Intern Med. 2012;172(12):909–19.

    Article  CAS  PubMed  Google Scholar 

  57. Collaboration CTT. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. 2015.

    Google Scholar 

  58. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air force/Texas coronary atherosclerosis prevention study. JAMA. 1998;279(20):1615–22. https://doi.org/10.1001/jama.279.20.1615.

    Article  CAS  PubMed  Google Scholar 

  59. Miettinen TA, Pyörälä K, Olsson AG, Musliner TA, Cook TJ, Faergeman O, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian simvastatin survival study (4S). Circulation. 1997;96(12):4211–8. https://doi.org/10.1161/01.cir.96.12.4211.

    Article  CAS  PubMed  Google Scholar 

  60. Lewis SJ, Moye LA, Sacks FM, Johnstone DE, Timmis G, Mitchell J, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the cholesterol and recurrent events (CARE) trial. Ann Intern Med. 1998;129(9):681–9. https://doi.org/10.7326/0003-4819-129-9-199811010-00002.

    Article  CAS  PubMed  Google Scholar 

  61. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339(19):1349–57. https://doi.org/10.1056/nejm199811053391902

  62. Waters D, Higginson L, Gladstone P, Boccuzzi SJ, Cook T, Lespérance J. Effects of cholesterol lowering on the progression of coronary atherosclerosis in women: a Canadian coronary atherosclerosis intervention trial (CCAIT) substudy. Circulation. 1995;92(9):2404–10.

    Article  CAS  PubMed  Google Scholar 

  63. Wild R, Weedin EA, Wilson D. Dyslipidemia in pregnancy. Cardiol Clin. 2015;33(2):209–15.

    Article  PubMed  Google Scholar 

  64. Ferriols E, Rueda C, Gamero R, Vidal M, Payá A, Carreras R, et al. Relationship between lipid alterations during pregnancy and adverse pregnancy outcomes. Clin Investig Arteriosclerosis. 2016;28(5):232–44. https://doi.org/10.1016/j.arteri.2015.04.003.

    Article  Google Scholar 

  65. Woollett LA. Maternal cholesterol in fetal development: transport of cholesterol from the maternal to the fetal circulation. Am J Clin Nutr. 2005;82(6):1155–61. https://doi.org/10.1093/ajcn/82.6.1155.

    Article  CAS  PubMed  Google Scholar 

  66. Woollett LA. Where does fetal and embryonic cholesterol originate and what does it do? Annu Rev Nutr. 2008;28:97–114. https://doi.org/10.1146/annurev.nutr.26.061505.111311.

    Article  CAS  PubMed  Google Scholar 

  67. Expert Panel on Detection E. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486.

    Google Scholar 

  68. Napoli C, Glass CK, Witztum JL, Deutsch R, D'Armiento FP, Palinski W. Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: fate of early lesions in children (FELIC) study. Lancet. 1999;354(9186):1234–41. https://doi.org/10.1016/s0140-6736(99)02131-5.

    Article  CAS  PubMed  Google Scholar 

  69. Wiznitzer A, Mayer A, Novack V, Sheiner E, Gilutz H, Malhotra A, et al. Association of lipid levels during gestation with preeclampsia and gestational diabetes mellitus: a population-based study. Am J Obstetrics Gynecol. 2009;201(5):482.e1–8. https://doi.org/10.1016/j.ajog.2009.05.032

  70. Avis HJ, Hutten BA, Twickler MT, Kastelein JJ, van der Post JA, Stalenhoef AF, et al. Pregnancy in women suffering from familial hypercholesterolemia: a harmful period for both mother and newborn? Curr Opin Lipidol. 2009;20(6):484–90. https://doi.org/10.1097/MOL.0b013e3283319127.

    Article  CAS  PubMed  Google Scholar 

  71. Thulasidass K, Chowdhury TA. Hypertriglyceridemic pancreatitis in pregnancy: case reports and review of the literature. JRSM Short Rep. 2013;4(8):2042533313481211. https://doi.org/10.1177/2042533313481211.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Edison RJ, Muenke M. Central nervous system and limb anomalies in case reports of first-trimester statin exposure. N Engl J Med. 2004;350(15):1579–82.

    Article  CAS  PubMed  Google Scholar 

  73. Ofori B, Rey E, Bérard A. Risk of congenital anomalies in pregnant users of statin drugs. Br J Clin Pharmacol. 2007;64(4):496–509.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Taguchi N, Rubin ET, Hosokawa A, Choi J, Ying AY, Moretti ME, et al. Prenatal exposure to HMG-CoA reductase inhibitors: effects on fetal and neonatal outcomes. Reprod Toxicol. 2008;26(2):175–7.

    Article  CAS  PubMed  Google Scholar 

  75. Winterfeld U, Allignol A, Panchaud A, Rothuizen L, Merlob P, Cuppers-Maarschalkerweerd B, et al. Pregnancy outcome following maternal exposure to statins: a multicentre prospective study. BJOG Int J Obstet Gynaecol. 2013;120(4):463–71.

    Article  CAS  Google Scholar 

  76. Costantine MM, Cleary K, Hebert MF, Ahmed MS, Brown LM, Ren Z, et al. Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial. Am J Obstetrics Gynecol. 2016;214(6):720.e1–e17.

    Google Scholar 

  77. Zarek J, Koren G. The fetal safety of statins: a systematic review and meta-analysis. J Obstet Gynaecol Can. 2014;36(6):506–9.

    Article  PubMed  Google Scholar 

  78. McGrogan A, Snowball J, Charlton RA. Statins during pregnancy: a cohort study using the general practice research database to investigate pregnancy loss. Pharmacoepidemiol Drug Saf. 2017;26(7):843–52.

    Article  PubMed  Google Scholar 

  79. Toleikyte I, Retterstøl K, Leren TP, Iversen PO. Pregnancy outcomes in familial hypercholesterolemia: a registry-based study. Circulation. 2011;124(15):1606–14.

    Article  PubMed  Google Scholar 

  80. Sanderson SL, Iverius P-H, Wilson DE. Successful hyperlipemic pregnancy. JAMA. 1991;265(14):1858–60.

    Article  CAS  PubMed  Google Scholar 

  81. Goldberg AS, Hegele RA. Severe hypertriglyceridemia in pregnancy. J Clin Endocrinol Metabol. 2012;97(8):2589–96. https://doi.org/10.1210/jc.2012-1250.

    Article  CAS  Google Scholar 

  82. Takaishi K, Miyoshi J, Matsumura T, Honda R, Ohba T, Katabuchi H. Hypertriglyceridemic acute pancreatitis during pregnancy: prevention with diet therapy and ω-3 fatty acids in the following pregnancy. Nutrition. 2009;25(11):1094–7. https://doi.org/10.1016/j.nut.2009.04.009.

    Article  CAS  PubMed  Google Scholar 

  83. Wild R, Weedin EA, Wilson D. Dyslipidemia in Pregnancy. Endocrinol Metab Clin N Am. 2016;45(1):55–63. https://doi.org/10.1016/j.ecl.2015.09.004.

    Article  Google Scholar 

  84. McKeage K, Keating GM. Fenofibrate: a review of its use in dyslipidaemia. Drugs. 2011;71(14):1917–46. https://doi.org/10.2165/11208090-000000000-00000.

    Article  CAS  PubMed  Google Scholar 

  85. Sivakumaran P, Tabak SW, Gregory K, Pepkowitz SH, Klapper EB. Management of familial hypertriglyceridemia during pregnancy with plasma exchange. J Clin Apher. 2009;24(1):42–6. https://doi.org/10.1002/jca.20192.

    Article  PubMed  Google Scholar 

  86. Kitler ME. Differences in men and women in coronary artery disease, systemic hypertension and their treatment. Elsevier; 1992.

    Book  Google Scholar 

  87. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, et al. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses’ Health Study. N Engl J Med. 1991;325(11):756–62.

    Article  CAS  PubMed  Google Scholar 

  88. Rosenberg L, Palmer JR, Shapiro S. Decline in the risk of myocardial infarction among women who stop smoking. N Engl J Med. 1990;322(4):213–7.

    Article  CAS  PubMed  Google Scholar 

  89. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA. 1996;275(20):1571–6.

    Article  CAS  PubMed  Google Scholar 

  90. Jansen SC, Temme EH, Schouten EG. Lifetime estrogen exposure versus age at menopause as mortality predictor. Maturitas. 2002;43(2):105–12.

    Article  CAS  PubMed  Google Scholar 

  91. Mosca L, Manson JE, Sutherland SE, Langer RD, Manolio T, Barrett-Connor E. Cardiovascular disease in women: a statement for healthcare professionals from the American Heart Association. Circulation. 1997;96(7):2468–82.

    Article  CAS  PubMed  Google Scholar 

  92. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991;20(1):47–63.

    Article  CAS  PubMed  Google Scholar 

  93. Boardman HM, Hartley L, Eisinga A, Main C, Figuls MR, Cosp XB, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev. 2015;3

    Google Scholar 

  94. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280(7):605–13.

    Article  CAS  PubMed  Google Scholar 

  95. Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med. 2000;343(8):522–9.

    Article  CAS  PubMed  Google Scholar 

  96. Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, et al. Menopausal hormone therapy and health outcomes during the intervention and extended Poststopping phases of the Women’s health initiative randomized trials. JAMA. 2013;310(13):1353–68. https://doi.org/10.1001/jama.2013.278040.

    Article  CAS  PubMed  Google Scholar 

  97. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the Management of Blood Cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2019;73(24):e285–350. https://doi.org/10.1016/j.jacc.2018.11.003.

    Article  PubMed  Google Scholar 

  98. Catov JM, Newman AB, Roberts JM, Kelsey SF, Sutton-Tyrrell K, Harris TB, et al. Preterm delivery and later maternal cardiovascular disease risk. Epidemiology. 2007:733–9.

    Google Scholar 

  99. Grandi SM, Vallée-Pouliot K, Reynier P, Eberg M, Platt RW, Arel R, et al. Hypertensive disorders in pregnancy and the risk of subsequent cardiovascular disease. Paediatr Perinat Epidemiol. 2017;31(5):412–21.

    Article  PubMed  Google Scholar 

  100. Ley SH, Li Y, Tobias DK, Manson JE, Rosner B, Hu FB, et al. Duration of reproductive life span, age at menarche, and age at menopause are associated with risk of cardiovascular disease in women. J Am Heart Assoc. 2017;6(11):e006713.

    Article  PubMed  PubMed Central  Google Scholar 

  101. Roeters Van Lennep JE, Heida KY, Bots ML, Hoek A, Disorders cotDMGDGoCRMaR. Cardiovascular disease risk in women with premature ovarian insufficiency: a systematic review and meta-analysis. Eur J Prev Cardiol. 2016;23(2):178–86.

    Article  PubMed  Google Scholar 

  102. Muka T, Oliver-Williams C, Kunutsor S, Laven JS, Fauser BC, Chowdhury R, et al. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis. JAMA Cardiol. 2016;1(7):767–76.

    Article  PubMed  Google Scholar 

  103. Welty FK. Dietary treatment to lower cholesterol and triglyceride and reduce cardiovascular risk. Curr Opin Lipidol. 2020;31(4):206–31.

    Article  CAS  PubMed  Google Scholar 

  104. Eckel RH, Jakicic JM, Ard JD, de Jesus JM, Miller NH, Hubbard VS, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014;63(25 Part B):2960–84.

    Google Scholar 

  105. Malik A, Kanduri JS, Asbeutah AAA, Khraishah H, Shen C, Welty FK. Exercise capacity, coronary artery fatty plaque, coronary calcium score, and cardiovascular events in subjects with stable coronary artery disease. J Am Heart Assoc. 2020;9(7):e014919.

    PubMed  PubMed Central  Google Scholar 

  106. Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, et al. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med. 2018;378(25):e34. https://doi.org/10.1056/NEJMoa1800389.

    Article  CAS  PubMed  Google Scholar 

  107. de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon diet Heart study. Circulation. 1999;99(6):779–85. https://doi.org/10.1161/01.cir.99.6.779.

    Article  PubMed  Google Scholar 

  108. Stewart RA, Wallentin L, Benatar J, Danchin N, Hagström E, Held C, et al. Dietary patterns and the risk of major adverse cardiovascular events in a global study of high-risk patients with stable coronary heart disease. Eur Heart J. 2016;37(25):1993–2001. https://doi.org/10.1093/eurheartj/ehw125.

    Article  PubMed  PubMed Central  Google Scholar 

  109. O’Keefe JH Jr, Harris WS. From Inuit to implementation: omega-3 fatty acids come of age. Mayo Clin Proc. 2000;75(6):607–14. https://doi.org/10.4065/75.6.607.

    Article  PubMed  Google Scholar 

  110. de Oliveira Otto MC, Wu JH, Baylin A, Vaidya D, Rich SS, Tsai MY, et al. Circulating and dietary omega-3 and omega-6 polyunsaturated fatty acids and incidence of CVD in the multi-ethnic study of atherosclerosis. J Am Heart Assoc. 2013;2(6):e000506. https://doi.org/10.1161/jaha.113.000506.

    Article  PubMed  PubMed Central  Google Scholar 

  111. Burr ML, Gilbert JF, Holliday RM, Elwood PC, Fehily AM, Rogers S, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet. 1989;334(8666):757–61. https://doi.org/10.1016/S0140-6736(89)90828-3.

    Article  Google Scholar 

  112. Mozaffarian D, Lemaitre RN, King IB, Song X, Spiegelman D, Sacks FM, et al. Circulating long-chain ω-3 fatty acids and incidence of congestive heart failure in older adults: the cardiovascular health study: a cohort study. Ann Intern Med. 2011;155(3):160–70. https://doi.org/10.7326/0003-4819-155-3-201108020-00006.

    Article  PubMed  PubMed Central  Google Scholar 

  113. Hu FB, Bronner L, Willett WC, Stampfer MJ, Rexrode KM, Albert CM, et al. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. JAMA. 2002;287(14):1815–21. https://doi.org/10.1001/jama.287.14.1815.

    Article  CAS  PubMed  Google Scholar 

  114. Hu Y, Hu FB, Manson JE. Marine omega-3 supplementation and cardiovascular disease: an updated meta-analysis of 13 randomized controlled trials involving 127 477 participants. J Am Heart Assoc. 2019;8(19):e013543. https://doi.org/10.1161/jaha.119.013543.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  115. Satija A, Bhupathiraju SN, Spiegelman D, Chiuve SE, Manson JE, Willett W, et al. Healthful and unhealthful plant-based diets and the risk of coronary Heart disease in U.S. adults. J Am Coll Cardiol. 2017;70(4):411–22. https://doi.org/10.1016/j.jacc.2017.05.047.

    Article  PubMed  PubMed Central  Google Scholar 

  116. Sotos-Prieto M, Bhupathiraju SN, Mattei J, Fung TT, Li Y, Pan A, et al. Association of changes in diet quality with total and cause-specific mortality. N Engl J Med. 2017;377(2):143–53. https://doi.org/10.1056/NEJMoa1613502.

    Article  PubMed  PubMed Central  Google Scholar 

  117. Welty FK. Preventing clinically evident coronary heart disease in the postmenopausal woman. Menopause. 2004;11(4):484–94.

    Article  PubMed  Google Scholar 

  118. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol. 2003;92(2):152–60.

    Article  CAS  PubMed  Google Scholar 

  119. Igase M, Kohara K, Tabara Y, Nagai T, Ochi N, Kido T, et al. Low-dose rosuvastatin improves the functional and morphological markers of atherosclerosis in asymptomatic postmenopausal women with dyslipidemia. Menopause. 2012;19(12):1294–9.

    Article  PubMed  Google Scholar 

  120. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation. 2002;106(8):1024–8.

    Article  PubMed  Google Scholar 

  121. McKenney JM, Davidson MH, Jacobson TA, Guyton JR. Final conclusions and recommendations of the national lipid association statin safety assessment task force. Am J Cardiol. 2006;97(8):S89–94.

    Article  CAS  Google Scholar 

  122. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7–22. https://doi.org/10.1016/s0140-6736(02)09327-3

  123. Newman CB, Palmer G, Silbershatz H, Szarek M. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Am J Cardiol. 2003;92(6):670–6. https://doi.org/10.1016/s0002-9149(03)00820-8.

    Article  CAS  PubMed  Google Scholar 

  124. Schrott HG, Bittner V, Vittinghoff E, Herrington DM, Hulley S. Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease. The Heart and estrogen/progestin replacement study (HERS). The HERS research group. JAMA. 1997;277(16):1281–6.

    Article  CAS  PubMed  Google Scholar 

  125. Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014;370:1809–19.

    Article  CAS  PubMed  Google Scholar 

  126. Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA. 2016;316(22):2373–84.

    Article  CAS  PubMed  Google Scholar 

  127. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–22.

    Article  CAS  PubMed  Google Scholar 

  128. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097–107.

    Article  CAS  PubMed  Google Scholar 

  129. van Heek M, Farley C, Compton DS, Hoos L, Davis HR. Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br J Pharmacol. 2001;134(2):409–17. https://doi.org/10.1038/sj.bjp.0704260.

    Article  PubMed  PubMed Central  Google Scholar 

  130. Ballantyne CM, Banach M, Mancini GBJ, Lepor NE, Hanselman JC, Zhao X, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. Atherosclerosis. 2018;277:195–203. https://doi.org/10.1016/j.atherosclerosis.2018.06.002.

    Article  CAS  PubMed  Google Scholar 

  131. Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbalán R, Špinar J, et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (improved reduction of outcomes: Vytorin efficacy international trial). Circulation. 2018;137(15):1571–82. https://doi.org/10.1161/circulationaha.117.030950.

    Article  CAS  PubMed  Google Scholar 

  132. Geng Q, Ren J, Chen H, Lee C, Liang W. Adverse events following statin-fenofibrate therapy versus statin alone: a meta-analysis of randomized controlled trials. Clin Exp Pharmacol Physiol. 2013;40(3):219–26. https://doi.org/10.1111/1440-1681.12053.

    Article  CAS  PubMed  Google Scholar 

  133. Vaklavas C, Chatzizisis YS, Ziakas A, Zamboulis C, Giannoglou GD. Molecular basis of statin-associated myopathy. Atherosclerosis. 2009;202(1):18–28. https://doi.org/10.1016/j.atherosclerosis.2008.05.021.

    Article  CAS  PubMed  Google Scholar 

  134. Rosenson RS. Current overview of statin-induced myopathy. Am J Med. 2004;116(6):408–16. https://doi.org/10.1016/j.amjmed.2003.10.033.

    Article  CAS  PubMed  Google Scholar 

  135. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Effects of icosapent ethyl on total ischemic events: from REDUCE-IT. J Am Coll Cardiol. 2019;73(22):2791–802. https://doi.org/10.1016/j.jacc.2019.02.032.

    Article  CAS  PubMed  Google Scholar 

  136. Alfaddagh A, Elajami TK, Saleh M, Mohebali D, Bistrian BR, Welty FK. An omega-3 fatty acid plasma index ≥4% prevents progression of coronary artery plaque in patients with coronary artery disease on statin treatment. Atherosclerosis. 2019;285:153–62. https://doi.org/10.1016/j.atherosclerosis.2019.04.213.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  137. Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, et al. Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl J Med. 2019;380(1):33–44. https://doi.org/10.1056/NEJMoa1809944.

    Article  CAS  PubMed  Google Scholar 

  138. Bernasconi AA, Wiest MM, Lavie CJ, Milani RV, Laukkanen JA, editors. Effect of Omega-3 dosage on cardiovascular outcomes: an updated meta-analysis and meta-regression of interventional trials. Mayo Clinic proceedings; 2020: Elsevier.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

    Nazanin Rajai & Francine K. Welty

Authors
  1. Nazanin Rajai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francine K. Welty
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francine K. Welty .

Editor information

Editors and Affiliations

  1. Department of Neurology, Seoul National University Hospital, Seoul, Korea (Republic of)

    Seung-Hoon Lee

  2. Department of Neurology, Uijeongbu Eulji Medical Center, Gyeonggi, Korea (Republic of)

    Min Kyoung Kang

Rights and permissions

Reprints and permissions

Copyright information

© 2021 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Rajai, N., Welty, F.K. (2021). Dyslipidemia in Women: Etiology and Management. In: Lee, SH., Kang, M.K. (eds) Stroke Revisited: Dyslipidemia in Stroke. Stroke Revisited. Springer, Singapore. https://doi.org/10.1007/978-981-16-3923-4_16

Download citation

  • DOI: https://doi.org/10.1007/978-981-16-3923-4_16

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-16-3922-7

  • Online ISBN: 978-981-16-3923-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation